Loading
A phase 2 trial of Zimberelimab, Domvanalimab, Sacituzumab govitecan in non-small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.
Study of Novel Treatment Combinations in Patients With Lung Cancer is a phase 2 interventional study registered as NCT05633667 by Gilead Sciences, with 192 participants enrolled, started 2023-03-16 and due to reach its primary completion in 2029-09. Interventions recorded: Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin. Conditions listed: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Domvanalimab, Zimberelimab, CD73 / adenosine axis, Gilead Sciences (incl. Kite).
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), T-cell exhaustion and CAR-T persistence.
Shares Domvanalimab, Zimberelimab, T-cell exhaustion and CAR-T persistence, Pemetrexed.
Shares Domvanalimab, Zimberelimab, CD73 / adenosine axis, Gilead Sciences (incl. Kite).
Shares Domvanalimab, Gilead Sciences (incl. Kite), T-cell exhaustion and CAR-T persistence, Non-small-cell lung cancer.
Shares Zimberelimab, Gilead Sciences (incl. Kite), Sacituzumab govitecan, Cisplatin.
Shares CD73 / adenosine axis, Pemetrexed, Carboplatin, Non-small-cell lung cancer.
Shares T-cell exhaustion and CAR-T persistence, Pemetrexed, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/